HEALTH OF WOMAN. 2019.6(142): 71–73; doi 10.15574/HW.2019.142.71
O.Yu. Kruk
I. Horbachevsky Ternopil State Medical University

The objective: to improve well-timed diagnostics of hyperplastic diseases the endometrium and mammary glands at women of perimenopause age on the basis of studying of the main clinical risk factors.
Materials and methods. Were surveyed 145 patients of perimenopause age, 15 from which (group of control) the women who didn’t have hyperplastic diseases of organs of genesial system (made of the contingent gynecological and mammology healthy).
Results. Clinical-anamnestic risk factors of the isolated hyperplastic process an endometrium are: early menarche, long and plentiful menses, inflammatory diseases of genitalias and use of endometrial methods of contraception. Probability of development of the isolated hyperplasia of mammary glands define: the burdened family anamnesis on a cancer of a mammary gland, the menarche, lack of a lactemia or its duration less than 6 months, pyoinflammatory diseases of mammary glands is later. By risk factors of the combined hyperplastic process in mammary glands and an endometrium are defined: the burdened family anamnesis on a cancer of a mammary gland, the menarche, a long becoming of a menstrual cycle (over a year) is later, than a disease of a thyroid gland and cardiac vascular system, numerous abortions. All taped clinical-anamnestic data indicate disturbance of endocrine balance at patients, both with isolated, and with the combined hyperplastic diseases an endometrium and mammary glands.
Conclusion. The received results needs to be considered when developing tactics of forecasting and early diagnostics of the combined pathology of uterus and mammary glands at women of perimenopause age.
Key words: hyperplastic processes of uterus and mammary glands, risk factors, perimenopause age.

REFERENCES

1. Tatarchuk TF, Efimenko OA, Islamova AO. 2013. Menopauza: novyiy vzglyad na staruyu problemu. Reproduktivnaya endokrinologiya 1(9):7-12.

2. Lole di Francesc Menopause State of the art. 2011: 540.

3. De Villiers TJ, Pines A, Panay N et al. 2013. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 16:316-37. https://doi.org/10.3109/13697137.2013.795683; PMid:23672656

4. Gold EB, Crawford SL, Avis NE et al. 2013. Factors related to age at natural menopause: longitudinal analyses from SWAN. Am J Epidemiol. 178:70-83. https://doi.org/10.1093/aje/kws421; PMid:23788671 PMCid:PMC3698989

5. Tobi de Viliers, Tatarchuk TF. 2016. Natsionalnyi konsensus shchodo vedennia patsiientok u klimakterii. Zdorove zhenshchynу 4(110):17-27.

6. Radzinskiy VE. 2017. Meditsina molochnoy zhelezyi i ginekologicheskie bolezni. Izd. 2-e, pererab. i dop. M, StatusPraesens: 345.

7. Tatarchuk TF, Kalugina LV. 2013. K voprosu o profilaktike i terapii gormonozavisimyih giperproliferativnyih zabolevaniy u zhenschin. Zdorove zhenschiny 7:51-7.

8. Naftalin J, Jurkovic D. 2013. The endometrial-myometrial junction: a fresh look at a busy crossing. Ultrasound Obstet. Gynecol. 34(1):1-11. https://doi.org/10.1002/uog.6432; PMid:19565525

9. Senchuk YaA, Pokrovenko OB. 2015. Sovremennyie podhodyi k vyiboru metoda lecheniya giperplasticheskih zabolevaniy endo– i miometriya. Ohrana materinstva i detstva. 1(21):64-7.

10. Kaminskiy VV, Prokopovich EV. 2017. Novyie aspektyi v lechenii leyomiomyi matki, assotsiirovannoy s endometriozom. Zdorove zhenschiny 3(119):32-5.

11. Prudnikov PM. 2017. Poiednannia adenomiozu i hiperplastychnykh protsesiv matky: udoskonalena taktyka diahnostyky ta likuvannia. Zdorove zhenschiny 7(123):132-34.